中国国际海运集装箱（集团）股份有限公司 关于回购股份事项前十大股东和前十大无限售条件股东 持股情况的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 中国国际海运集装箱（集团）股份有限公司（以下简称"公司"或"本公司"）于 2025 年 9 月 29 日召开了第十一届董事会 2025 年度第 10 次会议，审议通过了《关于回 购部分 A 股股份方案的议案》，具体内容详见公司于 2025 年 9 月 30 日在巨潮资讯网 （www.cninfo.com.cn）、本公司网站（www.cimc.com）披露的公告（公告编号：【CIMC】 2025-088 及【CIMC】2025-089）。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号— —回购股份》等相关规定，现将 2025 年 9 月 29 日登记在册的前十大股东和前十大无限 售条件股东的名称、持股数量和持股比例等情况公告如下： | 序号 | 股东名称 | 持股数量（股） | 占总股本比例 | 股份种类 | | --- | --- | --- | --- | --- | | 1 | ...

Group 1 - Company announced a share buyback plan during the 10th meeting of the 11th Board of Directors on September 29, 2025 [1] - The top ten unrestricted shareholders hold approximately 38.75 billion shares, accounting for 71.88% of total shares [1] - Major shareholders include Hong Kong Central Clearing with about 3.141 billion shares (58.25%) and Shenzhen Liyue Industrial Group with about 275 million shares (5.1%) [1] Group 2 - For the first half of 2025, the revenue composition of the company is as follows: containers 27.7%, logistics services 17.68%, energy and chemical equipment 16.88%, road transport vehicles 11.15%, marine engineering 10.44%, and other industries 6.87% [2] - The current market capitalization of the company is 44.7 billion yuan [2]

Core Viewpoint - China International Marine Containers (Group) Co., Ltd. (CIMC) has approved a plan to repurchase a portion of its A-shares to enhance company value and protect shareholder interests [3][6][19]. Group 1: Board Meeting Details - The 10th meeting of the 11th Board of Directors for the year 2025 was held on September 29, 2025, via written communication, with all nine directors participating [2][5]. - The meeting complied with relevant regulations including the Company Law and Securities Law of the People's Republic of China [2]. Group 2: Share Repurchase Plan - The company plans to use its own funds to repurchase A-shares, with a total repurchase amount not exceeding RMB 5 billion and not less than RMB 3 billion [6][11]. - The maximum repurchase price is set at RMB 12.01 per share, with an estimated repurchase quantity ranging from approximately 2.5 million to 4.16 million shares, representing 0.46% to 0.77% of the total issued share capital [6][11][12]. - The repurchased shares will be used to maintain company value and shareholder rights, with potential future adjustments for employee stock ownership plans or equity incentives [9][19]. Group 3: Implementation and Authorization - The authorization for the repurchase is effective from the date of the board's approval until the completion of the related matters [4][22]. - The board has authorized the chairman or designated personnel to manage the repurchase process, including deciding on the specific plan, timing, and scale [3][22]. Group 4: Financial Impact and Conditions - As of June 30, 2025, the company's total assets were approximately RMB 175.44 billion, with cash and cash equivalents around RMB 26.06 billion, indicating that the repurchase amount will not significantly impact the company's financial stability [17][18]. - The repurchase is expected to be completed within three months from the board's approval, with provisions for extension if necessary [13][14]. Group 5: Disclosure and Compliance - The company will disclose the progress of the repurchase regularly, including any adjustments to the use of repurchased shares [24]. - There are no current plans for share reduction by major shareholders or management, ensuring compliance with relevant regulations [19][20].

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Core Insights - The article highlights the significant net inflow of main funds into specific stocks over a period of five days or more, indicating strong investor interest and potential growth opportunities in these companies [1][2] Group 1: Key Stocks with Net Inflows - Cambrian Biologics-U (688256) leads with a continuous net inflow for 30 days, totaling 4.192 billion CNY, with a price increase of 41.87% [1] - Huayou Cobalt (603799) follows with a net inflow of 1.829 billion CNY over five days, reflecting a 25.57% increase [1] - Zhongnan Media (601098) has seen a net inflow for eight days, amounting to 1.111 billion CNY, with a minimal price change of 0.16% [2] Group 2: Notable Inflow Metrics - The highest net inflow percentage relative to trading volume is observed in Hebang Biology (603077), with a 13.89% ratio and a price increase of 8.90% over five days [1] - The total net inflow for Cambrian Biologics-U over 30 days is 4.192 billion CNY, indicating strong market confidence [1] - Other notable stocks include Tianqi Lithium (002466) with a net inflow of 576 million CNY and a price increase of 11.09% [1]

Group 1: Major Asset Restructuring - Guolin Technology is planning a significant asset restructuring by acquiring 91.07% of Xinjiang Kailianjie Petrochemical Co., Ltd. for cash, which will give the company control over Kailianjie, making it a subsidiary [1][2] Group 2: Equity Purchases and Stock Suspension - Diaowei is planning to purchase equity in Rongpai Semiconductor through a combination of issuing shares and cash payments, leading to a stock suspension from September 29, 2025, for up to 10 trading days [3] - Bicheng Co. is also planning to acquire 55% of Shanghai Canxi Engineering Equipment Co., Ltd. through issuing shares and cash, with a stock suspension starting September 30, 2025, for up to 5 trading days [7] Group 3: Changes in Control - Shanhe Pharmaceutical Auxiliary announced a change in its controlling shareholder and actual controller to Wu Changhong due to the inheritance following the death of the previous controller, Yin Zhenglong [4] Group 4: Earnings Forecasts - Yinglian Co. expects a net profit of 34.5 million to 37.5 million yuan for the first three quarters of 2025, representing a year-on-year increase of 1531.13% to 1672.97%, driven by the fast-moving consumer goods metal packaging sector [5] - Dalian Heavy Industry anticipates a net profit of 474 million to 508 million yuan for the same period, reflecting a growth of 19.91% to 28.52% year-on-year, attributed to steady revenue growth [5] Group 5: Fundraising and Projects - Zhongcai Technology plans to raise up to 4.481 billion yuan through a private placement to fund projects related to low dielectric fiber cloth production and to repay government funds [8] - Luoxin Pharmaceutical is also looking to raise up to 842.4 million yuan for innovative drug research and development and facility upgrades [8] Group 6: Regulatory Actions - *ST Xingnong has been investigated by the China Securities Regulatory Commission for suspected information disclosure violations [9] - Other companies, including Youkeshi and Woton Technology, are also involved in various regulatory and investment activities, including share buybacks and strategic partnerships [10][14]

Core Viewpoint - The company, through its wholly-owned subsidiary SG XINDE INVESTMENT (HK) LIMITED, plans to acquire a 40% stake in the target company, CIMC Xinde Leasing (Shenzhen) Co., Ltd., for approximately RMB 482 million, aiming to enhance its operational capabilities and market influence in the shipping industry [1][2]. Group 1: Acquisition Details - The acquisition involves a purchase price of approximately RMB 482 million for a 40% stake in the target company [1]. - The target company is primarily engaged in container, vessel, and general leasing services, as well as investment activities using its own funds [1][2]. - Upon completion of the acquisition, the ownership structure will be 40% for the company, 20% for the seller, and 40% for CIMC Group [1]. Group 2: Strategic Objectives - The acquisition aims to integrate shipping operations, management, investment, and financing to establish a circular ecosystem across the maritime value chain [2]. - The company expects to leverage resources from CIMC Group and the seller to enhance market influence and achieve operational synergies [2]. - The acquisition will extend the maritime industry chain, creating a one-stop maritime service platform covering the entire lifecycle of ship design, construction, financing, management, and operation [2]. Group 3: Financial Implications - The company will provide guarantees to ensure the target company can secure operational funding, which is crucial for its main business activities [2]. - A guarantee agreement will be established by October 2025, covering a loan amount of USD 40.44 million along with associated interests, costs, and expenses [1].

Core Viewpoint - CIMC Group has been actively repurchasing its shares, indicating a strategy to support its stock price amidst recent fluctuations [2][3] Share Buyback Summary - On September 29, CIMC Group repurchased 464,400 shares at a price range of HKD 7.770 to HKD 7.990, totaling HKD 3.6939 million [2] - The stock closed at HKD 7.960 on the same day, reflecting a 2.45% increase, with a total trading volume of HKD 13.1183 million [2] - Since September 15, the company has conducted share buybacks for 11 consecutive days, acquiring a total of 14.162 million shares for a cumulative amount of HKD 110 million, despite a 1.61% decline in the stock price during this period [2] Year-to-Date Buyback Activity - Year-to-date, CIMC Group has executed 35 buyback transactions, acquiring a total of 25.7942 million shares for a total expenditure of HKD 190 million [3] - Detailed buyback data shows varying amounts and prices, with the highest buyback occurring on September 24, where 581,370 shares were repurchased at a maximum price of HKD 7.830, totaling HKD 44.8824 million [3][4]

Group 1 - The company, CIMC Group, announced a share repurchase plan amounting to between 300 million to 500 million yuan [1] - The maximum repurchase price is set at 12.01 yuan per share [1]

Core Viewpoint - China International Marine Containers Group (CIMC) plans to repurchase shares worth no more than RMB 500 million and no less than RMB 300 million, with a maximum repurchase price of RMB 12.01 per share [1] Summary by Relevant Sections - **Repurchase Amount and Price** CIMC intends to repurchase shares with a total amount ranging from RMB 300 million to RMB 500 million, with a maximum price set at RMB 12.01 per share [1] - **Estimated Number of Shares** If the repurchase amount reaches the upper limit of RMB 500 million, approximately 41.63 million shares will be repurchased, accounting for about 0.77% of the company's total issued share capital. Conversely, if the repurchase amount is at the lower limit of RMB 300 million, around 24.98 million shares will be repurchased, representing about 0.46% of the total issued share capital [1]